76562-66-8

Upstream product

• 19873-46-2 N-Methyl-N'-(4-tolyl)harnstoff 
• 53681-52-0 C₁₂H₁₃N₃O₂ 

Downstream Products

• 176379-51-4 8-(3,5-di-tert-butyl-4-hydroxyphenyl)-1-methyl-3-(4-methylphenyl)purine-2,6-dione 
• 76562-51-1 (1-Methyl-2,6-dioxo-3-p-tolyl-2,3,6,9-tetrahydro-1H-purin-8-yl)-carbamic acid ethyl ester 
• 76562-50-0 (1-Methyl-2,6-dioxo-3-p-tolyl-2,3,6,9-tetrahydro-1H-purin-8-yl)-carbamic acid methyl ester 

Relevant academic research and scientific papers

Synthesis and biological evaluation of novel orally available 1-phenyl-6-aminouracils containing dimethyldihydrobenzofuranol structure for the treatment of allergic skin diseases

We have designed and efficiently synthesized novel 1-phenyl-6-aminouracils by replacing the chroman moiety in CX-659S, a nonsteroidal dermatologic candidate, with dimethyldihydrobenzofuranol to cancel CX-659S asymmetric center. Medicinal chemistry effort culminated in the discovery of 13d bearing a 3-methyl group at the 1-phenyl group as a promising compound. Compound 13d, having good in vitro ADME profile and moderate oral bioavailability in mice, showed potent anti-inflammatory activity against hapten-induced contact hypersensitivity reaction in mice following topical and oral administration. The effects of 13d were equipotent to that of tacrolimus or prednisolone. In addition, compound 13d, having potent hydroxyl radical-scavenging activity, showed more potent suppressive effect on substance P-induced pruritus in mice than oxatomide.

1-arylpyrimidine derivatives and pharmaceutical use thereof

The present invention relates to 1-arylpyrimidine derivatives represented by general formula (I): STR1 wherein R1 is H, alkyl or aralkyl; Ar is 1-naphthyl, or a substituted or unsubstituted phenyl group; R4 is a substituted phenyl, a substituted styryl, 1-methylcyclohexyl, 4-methylcyclohexyl, 4-oxo-4H-pyran-2-yl or 2-oxo-2H-pyran-5-yl group; R5 and R6 are each independently H or alkyl; R3 is H, and R7 and R8 are combined together to be oxo, or else R3 and R7 are combined together to be another direct bond, and R5 and R8 are combined together to be a direct bond, or pharmaceutically acceptable salts thereof; and methods for treating allergic diseases with such compounds.